Nicholas Grund Sells 55,621 Shares of Akebia Therapeutics, Inc. (NASDAQ:AKBA) Stock

Akebia Therapeutics, Inc. (NASDAQ:AKBA) insider Nicholas Grund sold 55,621 shares of the firm’s stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $2.10, for a total transaction of $116,804.10. Following the sale, the insider now owns 442,579 shares in the company, valued at approximately $929,415.90. The trade was a 11.16 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Akebia Therapeutics Stock Up 1.4 %

Shares of AKBA stock opened at $2.17 on Thursday. Akebia Therapeutics, Inc. has a 12 month low of $0.80 and a 12 month high of $2.48. The company’s fifty day simple moving average is $2.00 and its 200-day simple moving average is $1.67. The firm has a market cap of $473.45 million, a PE ratio of -9.43 and a beta of 0.74.

Akebia Therapeutics (NASDAQ:AKBA) last issued its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.06). The business had revenue of $37.43 million for the quarter, compared to analysts’ expectations of $45.66 million. During the same quarter in the previous year, the business earned ($0.08) earnings per share. On average, equities analysts predict that Akebia Therapeutics, Inc. will post -0.3 earnings per share for the current fiscal year.

Analyst Ratings Changes

AKBA has been the subject of a number of research reports. HC Wainwright reiterated a “buy” rating and set a $7.50 target price on shares of Akebia Therapeutics in a report on Thursday, January 23rd. StockNews.com downgraded Akebia Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, January 15th.

Institutional Trading of Akebia Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of AKBA. SRS Capital Advisors Inc. bought a new position in Akebia Therapeutics in the fourth quarter valued at approximately $26,000. B. Riley Wealth Advisors Inc. acquired a new stake in shares of Akebia Therapeutics in the 2nd quarter valued at approximately $44,000. Empirical Asset Management LLC bought a new position in shares of Akebia Therapeutics in the third quarter valued at $44,000. XTX Topco Ltd acquired a new position in Akebia Therapeutics during the third quarter worth $58,000. Finally, Intech Investment Management LLC bought a new stake in Akebia Therapeutics during the third quarter worth $59,000. Institutional investors and hedge funds own 33.92% of the company’s stock.

Akebia Therapeutics Company Profile

Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company’s lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients.